Scientific Reports (May 2023)

Optimising the yield from bronchoalveolar lavage on human participants in infectious disease immunology research

  • Jane Alexandra Shaw,
  • Maynard Meiring,
  • Devon Allies,
  • Lauren Cruywagen,
  • Tarryn-Lee Fisher,
  • Kesheera Kasavan,
  • Kelly Roos,
  • Stefan Marc Botha,
  • Candice MacDonald,
  • Andriёtte M. Hiemstra,
  • Donald Simon,
  • Ilana van Rensburg,
  • Marika Flinn,
  • Ayanda Shabangu,
  • Helena Kuivaniemi,
  • Gerard Tromp,
  • Stephanus T. Malherbe,
  • Gerhard Walzl,
  • Nelita du Plessis,
  • The Stellenbosch University Immunology Research Group Bronchoalveolar Lavage Study Consortium (SU IRG BAL Study Consortium)

DOI
https://doi.org/10.1038/s41598-023-35723-2
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Bronchoalveolar lavage (BAL) is becoming a common procedure for research into infectious disease immunology. Little is known about the clinical factors which influence the main outcomes of the procedure. In research participants who underwent BAL according to guidelines, the BAL volume yield, and cell yield, concentration, viability, pellet colour and differential count were analysed for association with important participant characteristics such as active tuberculosis (TB) disease, TB exposure, HIV infection and recent SARS-CoV-2 infection. In 337 participants, BAL volume and BAL cell count were correlated in those with active TB disease, and current smokers. The right middle lobe yielded the highest volume. BAL cell and volume yields were lower in older participants, who also had more neutrophils. Current smokers yielded lower volumes and higher numbers of all cell types, and usually had a black pellet. Active TB disease was associated with higher cell yields, but this declined at the end of treatment. HIV infection was associated with more bloody pellets, and recent SARS-CoV-2 infection with a higher proportion of lymphocytes. These results allow researchers to optimise their participant and end assay selection for projects involving lung immune cells.